Pharmacological inhibition of leukotriene actions

Pharmacy World and Science

Volumn 20, Issue 2, 1998, Pages 60-65

  Engels, F ^a   Nijkamp, F P ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Enzyme inhibitors; Leukotrienes; Receptor antagonists; Zafirlukast; Zileuton

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 5 ETHYL 2 HYDROXY 4 [6 METHYL 6 (1H TETRAZOL 5 YL)HEPTYLOXY]ACETOPHENONE; 7 [3 (4 ACETYL 3 METHOXY 2 PROPYLPHENOXY)PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 CARBOXYLIC ACID; AZELASTINE; CETIRIZINE; EBASTINE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MANOALIDE; MONTELUKAST; PHOSPHOLIPASE A2 INHIBITOR; POBILUKAST; PRANLUKAST; PROBILUKAST; SCALARADIAL; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ALLERGY; ANAPHYLAXIS; ARACHIDONIC ACID METABOLISM; ASTHMA; BRONCHODILATATION; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; HUMAN; IMMUNOREGULATION; MEDIATOR RELEASE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES;

EID: 0031959721     PISSN: 09281231     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008698027211     Document Type: Review

References (69)

1. Feldberg W, Kellaway CH. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J Physiol 1938;94: 187-226.
2. Kellaway CH, Trethewie ER. The liberation of a slow reacting smooth muscle-stimulating substance in anaphylaxis. QJ Exp Physiol 1940;30: 121-45.
3. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979;76: 4275-9.
4. Denzlinger C. Biology and pathophysiology of leukotrienes. Crit Rev Oncol Hematol 1996;23: 167-223.
5. Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase. Ann Rev Biochem 1994;63: 383-417.
6. Nagy L, Lee TH, Goetzl EJ, Pickett WC, Kay AB. Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products. Clin Exp Immunol 1982;47: 541-7.
7. 4 action on endothelium mediates augmented neutrophil endothelial adhesion. Proc Natl Acad Sci USA 1984;81: 2191-3.
8. 4, and histamine in normal human subjects. Thorax 1984;39: 500-4.
9. 4 enhance histamine responsiveness in asthmatic airways. Am Rev Respir Dis 1991;144: 1053-7.
10. 4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc Natl Acad Sci USA 1986;83: 2204-8.
11. 4. Am J Pathol 1987;126: 19-24.
12. Dahlén SE, Bjork J, Hedqvist P. Leukotrienes promote plasma leakage and leukocyte adhesion in post capillary venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 1981;78: 3887-91.
13. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982;126: 449-51.
14. 4 and granulocytic infiltration into asthmatic airways. Lancet 1993;341: 989-90.
15. 2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 1980;77: 2533-6.
16. Chung KF, Wiggins J, Collins J. Corticosteroids. In: Weiss EB, Stein M, eds. Bronchial Asthma. Mechanisms and Therapeutics. Boston: Little, Brown and Company, 1993: 800-17.
17. 2 inhibitors, Int Arch Allergy Immunol 1995;107:432-4.
18. 2. Biochem Pharmacol 1986;35: 449-53.
19. Cimino G, DeStefano S, Minale L. Scalaradial, a third sesterterpene with the tetracarbocyclic skeleton of scalarin, from the sponge Cacospongia mollior. Experientia 1974;30: 846-7.
20. 2 with anti-inflammatory activity. Biochem Pharmacol 1997;53: 733-40.
21. 2 inhibitors from ascomycetes. J Antibiot 1991,44: 1467-70.
22. McMillan RM, Girodeau JM, Foster SJ. Selective chiral inhibitors of 5-lipoxygenase with anti-inflammatory activity. Br J Pharmacol 1990;101:501-3.
23. Hui KP, Taylor IK, Taylor GW, Rubin P, Kesterson J, Barnes NC. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991,46: 184-9.
24. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P, Drazen JM. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. The New Engl J Med 1990;323: 1740-4.
25. Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148: 1447-51.
26. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153: 931-5.
27. Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993;119: 1059-66.
28. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. J Am Med Assoc 1996;275: 931-6.
29. Liu MC, Dubé LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996;98: 859-71.
30. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. The New Engl J Med 1990;323: 1745-8.
31. Weinblatt ME, Kremer JM, Coblyn JS, Helfgott S, Maier AL, Petrillo G, Henson B, Rubin P, Sperling R. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 1992;19: 1537-41.
32. Collawn C, Rubin P, Pérez N, Reyes E, Bobadilla J, Cabrera G, Morän MA, Kershenobich D. Experimental use of a 5-lipoxygenase inhibitor (Abbott - 64077) in human ulcerative colitis (UC). Am J Gastroenterol 1989;84: 1178.
33. Bukhave K, Laursen LS, Lauritsen K, Rask-Madsen J, Naesdal J, Jacobson O, Goebell H, Peskar B, Cort D, Stenson W, Hanauer S. 5-Lipoxygenase inhibition in double-blind trial with zileuton: how much is sufficient in active ulcerative colitis? Gastroenterology 1991;-100: A200.
34. FDA gives year-end okays to a baker's dozen new drugs. Physician's Weekly (1997) Vol. XIV, No. 5.
35. Crawley GC, Dowell RI, Edwards PN, Foster SJ, McMillan RM, Walker ER, Waterson D, Bird TG, Bruneau P, Giroaeau JM. Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J Med Chem 1992;35: 2500-9.
36. Nasser SM, Bell GS, Foster S, Spruce K, MacMillan R, Williams AJ, Arm JP, Lee TH. Effect of ZD21 38 in aspirin-induced asthma and on the allergen-induced early and late asthmatic responses. J Allergy Clin Immunol 1994;93: 680.
37. Nasse SM, Bell GS, Hawksworth RJ, Spruce KE, MacMillan R, Williams AJ, Lee TH, Arm PJ. Effect of the 5-lipoxygenase inhibitor ZD21 38 on allergen-induced early and late asthmatic responses. Thorax 1994;49: 743-8.
38. Friedman BS, Bel EH, Buntinx A, Tanaka W, Han YH, Shingo S, Spector R, Sterk P. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993;147: 839-44.
39. Diamant Z, Timmers MC, Van der Veen H. The effect of MK-0591, a noval 5-lipoxygenase activating protein (FLAP) inhibitor, on leukotriene biosynthesis and allergen-induced air-way responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95: 42-51.
40. Dahlén SE, Dahlén B, Ihre E, Kumlin M, Franzén L, Stensvad F, Larsson C, Blomqvist H, Björck T, Zetterström O. The leukotriene biosynthesis inhibitor BAY x1005 is a potent inhibitor of allergen-induced airway obstruction and leukotriene formation in man. Am Rev Respir Dis 1993;147: A837.
41. 4 synthase: therapeutic targets for inhibiting the leukotriene cascade. Adv Prostagl Thrombox Leukotr Res 1994;22: 13-21.
42. 4 hydrolase. Implications for the development of enzyme inhibitors. Adv Prostagl Thrombox Leukotr Res 1994;22: 3-12.
43. Coleman RA, Eglen RM, Jones RL, Narumiya S, Shimizu T, Smith WL, Dahlén SE, Drazen JM, Gardiner PJ, Jackson WT, Jones TR, Krell RD, Nicosia S. Prostanoid and leukotriene receptors: a progress report from the IUPHAR working parties on classification and nomenclature. Adv Prostagl Thrombox Leukotr Res 1995;23: 283-5.
44. 4 receptor antagonist SC-41930 on colonic inflammation in rat, guinea pig and rabbit. J Pharmacol Exp Ther 1990;255: 572-6.
45. 4 receptor antagonist, in the guinea pig model of middle ear inflammation. Ann Otol Rhinol Laryngol 1996;105:476-80.
46. 4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs. Surgery 1993;114: 191-8.
47. 4 receptor antagonists. J Med Chem 1994;37: 3327-36.
48. 4 antagonism in a primate model of asthma. J Clin Invest 1996;97: 381-7.
49. Fitzsimmons BJ and Rokach J. Enzyme inhibitors and leukotriene receptor antagonists. In: Rokach J, ed. Leukotrienes and lipoxygenases. Chemical, biological and clinical Aspects. Amsterdam: Elsevier Science Publishers: 1989: 427-502.
50. 4 receptor antagonist ICI 204,219. Am Rev Respir Dis 1990;141: 988-92.
51. 4-induced bronchoconstriction in the human. Am Rev Respir Dis 1991;144: 617-21.
52. Taylor IK, O'Shaughnessy KM, Fuller RM, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 1991;337: 691-4.
53. Findlay SR, Barden JM, Easley CB, Glass M. Effect of the oral leukotriene antagonist ICI 204,219 on the antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 1992;89: 1040-5.
54. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992;90: 193-201.
55. 4 receptor antagonist. The New Engl J Med 1990;323: 1736-9.
56. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147: 1413-8.
57. Robuschi M, Riva E, Fuccella LM, Vida E, Barnabe R, Rossi M, Gambaro G, Spagnotto S, Bianco S. Prevention of exerciseinduced bronchoconstriction by a new leukotriene antagonist (SK&F 104353). A double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992;145: 1285-8.
58. 4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995;151: 1734-9.
59. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104,353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144: 957-8.
60. Dahlén B, Kumlin M, Margolskee DJ, Larsson C, Blomqvist H, Williams VC, Zetterstrom O, Dahlén SE. The leukotrienereceptor antagonist MK-0679 blocks the airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993;6:1018-26.
61. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, Zhang J. Effects of montelukast (MKM-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilatation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52: 45-8.
62. Bel H, Timmers MC, Dijkman JH, Stahl EG, Sterk PJ. The effect of an inhaled leukotriene antagonist, L-648,051, on early and late asthmatic reactions and subsequent increase in airway responsiveness in man. J Allergy Clin Immunol 1990;85: 1067-75.
63. Fujimura M, Sakamoto S, Kamio Y, Matsuda T. Effect of a leukotriene antagonist. ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Resp Med 1993;87: 133-8.
64. 4 production by blood neutrophils in allergic rhinitis - effects of cetirizine. Clin Exp Allergy 1995;25: 729-36.
65. Kalayci O, Saraclar Y, Adalioglu G, Sekerel B, Tuncer A. The effect of cetirizine on sulfidoleukotriene production by blood leukocytes in children with allergic rhinitis. Allergy 1995;50: 964-9.
66. Dobashi K, lizuka K, Houjou S, Sakai H, Watanabe K, Mori M, Nakazawa T. Effect of cetirizine on antigen-induced tracheal contraction of passively sensitized guinea pigs. Ann Allergy Asthma Immunol 1996;77: 310-8.
67. Campbell A, Michel F-B, Bremard-Oury C, Crampette L, Bousquet J. Overview of allergic mechanisms. Ebastine has more than antihistamine effect. Drugs 1996;52: 15-9.
68. Hamasaki Y, Shafigeh M, Yamamoto S, Sato R, Zaitu M, Muro E, Kobayashi I, Ichimaru T, Tasaki H, Miyazaki S. Inhibition of leukotriene synthesis by azelastine. Ann Allergy Asthma Immunol 1996;76: 69-75.
69. Fresh Breath. First leukotriene antagonist is okayed. Physician's Weekly (1996);Vol. XIII, No. 41.